Source link : https://www.newshealth.biz/health-news/durvalumab-wins-fda-approval-in-limited-stage-sclc/
The FDA expanded the indications for the immune checkpoint inhibitor durvalumab (Imfinzi) to include limited-stage small cell lung cancer (SCLC). Approval stipulates use of the PD-L1 inhibitor in limited-stage SCLC that has not progressed following platinum-based concurrent chemoradiation. Support for the approval came from the phase III ADRIATIC trial of 730 patients with stage I-III […]
Author : News Health
Publish date : 2024-12-05 14:15:50
Copyright for syndicated content belongs to the linked Source.